OR WAIT 15 SECS
© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
© 2020 MJH Life Sciences™ and Drug Topics. All rights reserved.
November 26, 2020
A study to be presented at the annual meeting of the Radiological Society of North America reported that COVID-19 patients with diabetes and hypertension may have a higher risk for neurologic complications.
November 09, 2020
What pharmacists need to know about helping patients navigate changing landscape.
November 05, 2020
Researchers reported that patients who received finerenone had a lower risk of kidney failure or death from renal causes.
October 27, 2020
A subgroup analysis of the DAPA-CKD phase 3 trial reported on the continued benefit of dapagliflozin in patients with chronic kidney disease, regardless of underlying cause.
October 09, 2020
Patients now have a variety of options to help them lose weight, and pharmacists can offer a variety of specialized services to support their patients’ needs.
September 30, 2020
Investigators compared SGLT2 inhibitors with DPP-4 inhibitors to evaluate their effects on the risk of major heart problems.
September 24, 2020
Sun Pharmaceuticals issued a voluntary recall of 1 lot of its metformin hydrochloride for extended-release (ER) oral suspension (Riomet ER), 500 mg per 5 mL.
September 23, 2020
In a post-hoc analysis, researchers reported the effects of semaglutide on kidney function in patients with type 2 diabetes.
September 21, 2020
The study marks the first pharmacoepigenetic study in diabetes evaluating epigenetic factors as biomarkers to predict a drug’s effects on an individual.
September 18, 2020
Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.